ReviewAllergologie select2022
Digital health for allergen immunotherapy.
Review in Allergologie select, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- Monitoring adherence and patient-reported outcomes during subcutaneous immunotherapy for house dust mites with the AllergyVax app/web platform.The journal of allergy and clinical immunology. Global · 2026Article
- Allergy to Cats: Current Perspectives and Therapeutic Options.Clinical and translational allergy · 2026Review
- Global Research Trends in Chronic Care for Comorbid Allergic Diseases: A Web of Science Bibliometric Review (1999-2024).Current allergy and asthma reports · 2025Review
- Preparing Allergists to Practice in 2050 Using Artificial Intelligence.The journal of allergy and clinical immunology. In practice · 2025Review
- The Impact of Artificial Intelligence on Allergy Diagnosis and Treatment.Current allergy and asthma reports · 2024Review
- COVID-19 in the Asia Pacific: Impact on climate change, allergic diseases and One Health.Asia Pacific allergy · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the recent past, digital healthcare technologies are experiencing a significant leap in development, with an additional unforeseen acceleration in implementation due to the SARS-CoV-2 pandemic. The increased use of mobile applications as well as communication technologies to search for services and support hold particular advantages for the management of chronic diseases requiring medium- to long-term treatments and regular follow-up visits. Allergen immunotherapy (AIT), requiring regular application of treatment, represents an optimal scenario for feasible digital support. From patient stratification and care pathways, over personalized decision support for complex clinical scenarios, towards a close and flexible patient-doctor communication in blended care settings: the current article summarizes the latest knowledge on the use and potential of digital health technologies in the area of AIT .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.